Skip To Main Content
P. Noel Barrett on Muck Rack

P. Noel Barrett

As seen in: Color Research & Application, Journal of Antimicrobial Chemotherapy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with P. Noel

Contact P. Noel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Acitretin as a successful treatment for Hailey-Hailey disease

|
By K. Naidoo, P. Noel Barrett, I. Tighe, V. Bajaj
| Wiley Online Library Verified
Corresponding Author E-mail address:vrinda.bajaj@nhs.net Department of Dermatology, University Hospital of North Durham, Durham, UK Correspondence: Dr Vrinda Bajaj, Department of Histopahology, University Hospital of North Durham, North Road, Durham, County Durham, DH1 5TW, UK E‐mail: vrinda.bajaj@nhs.net Search for more papers by this author
Open in Who Shared Issue with article?

A text on which the ink never dries: dialogical practices for care and treatment planning

|
By P. Noel Barrett, P. Linsley
| Color Research & Application Verified
Previous article in Early View: ‘Your experiences were your tools’. How personal experience of mental health problems informs mental health nursing practice Previous article in Early View: ‘Your experiences were your tools’. How personal experience of mental health problems informs mental health nursing practice
Open in Who Shared Issue with article?

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

|
By Didier Scherrer, Regine Rouzier, P. Noel Barrett, Jean-Marc Steens
| Journal of Antimicrobial Chemotherapy Verified
Background: An anti-HIV compound (ABX464) has been developed with a novel mechanism of activity in that it blocks viral gene expression in cells that are already infected. Objectives: A first-in-man study was conducted to determine the pharmacokinetic and safety profiles of ABX464. This was carried out as an open label, parallel group, single ascending dose, exploratory study.
Open in Who Shared Issue with article?
See all 3 articles